A Phase 3 interventional study of SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) and Placebo (Initial Vaccination Period) in SARS-CoV Infection and Covid19, sponsored by Novavax. Completed at 154 sites in 3 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.
Sponsored by Novavax · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Severe Acute Respiratory Syndrome with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · United States.
Among the 106 studies in Severe Acute Respiratory Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 79 interventional ones that give a count, is one of 61 that started in 2020, is one of 27 in phase 3, and was the 70th registered.
376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.
Browse Severe Acute Respiratory Syndrome studies →5 of the 106 studies in Severe Acute Respiratory Syndrome with a site in United States are open now. Recruiting first, the newest first:
Cantor BioConnect, Inc. · Sites in United States
Ages 5+ · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 36 more countries
Ages 18+
CellSight Technologies, Inc. · Sites in United States
Ages 18+
OMNI Medical Services, LLC · Sites in United States
Ages 7+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 35 · Phase 3 31 · Phase 4 4
First in 2003; this study’s year is marked. 61 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33,000 is above the median of 140 across 210 interventional studies indexed under Severe Acute Respiratory Syndrome.
Median enrollment 100 across the 79 interventional studies, 345 across the 24 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 106 have an industry lead sponsor. The 10 most frequent:
Novavax is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
Novavax has 2 studies filed under Severe Acute Respiratory Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Severe Acute Respiratory Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04705766University of California, San FranciscoKIDney Injury in Times of COVID-19 (KIDCOV) | 2027-03 |
| NCT04815096CellSight Technologies, Inc.Imaging Immune Activation in COVID-19 | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 106 studies in Severe Acute Respiratory Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants. Additionally providing a Booster Dose to fully vaccinated participants. A substudy is to be conducted at selected sites to evaluate the safety and immunogenicity of a fourth dose (second booster) of NVX-CoV2373 in adults and adolescents, previously fully vaccinated and subsequently boosted with a third dose (first booster)
This is a Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants ≥ 18 years of age (Adult Main Study) and adolescent participants 12 to \<18 years (Pediatric Expansion). Additionally, a Booster Amendment will allow for the evaluation of a booster dose of SARS-CoV-2 rS with Matrix-M1 adjuvant in participants who completed the primary series of active vaccine in the Adult Main Study or Pediatric Expansion, as well as in participants who previously completed the primary series of an authorized/approved COVID-19 vaccine. Additionally, a sub-study conducted at specific sites will allow for the evaluation of a second booster dose of SARS-CoV-2 rS with Matrix-M1 adjuvant in participants who completed the primary series of active vaccine in the Adult Main Study and Pediatric Expansion as well as a booster dose in the Booster Amendment of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult Participants :
Each participant in the Adult Main Study and/or the Booster Amendment must meet all of the following criteria to be enrolled in this study:
Pediatric Participants :
Each participant in the Pediatric Expansion and/or the Booster Amendment must meet all of the following criteria to be enrolled in this study:
Site-Specific Sub Study:
Each participant in the Substudy must meet all of the following criteria to be enrolled in this study:
Note: For participants who develop COVID-19, anti-SARS-CoV-2 therapy (approved, authorized or ) is permitted.
Exclusion Criteria:
Adult and adolescent participants meeting any of the following criteria will be excluded from the study:
Unstable acute or chronic illness. Criteria for unstable medical conditions include:
Note: Well-controlled [HIV] with undetectable HIV RNA [\< 50 copies/mL] and > 200 cells/µL for at least 1 year, documented within the last 6 months, is NOT considered an unstable chronic illness. Participant's or parent's/caregiver's verbal report will suffice as documentation.
Adult and adolescent participants meeting any of the following criteria will be excluded from the substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period.
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
2 doses of Placebo (Saline), 1 dose each on Days 0 and 21in Initial Vaccination Period.
Other: Placebo (Initial Vaccination Period)
One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Booster Vaccination Period.
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Second Booster Vaccination Period.
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.
Other: Placebo (Crossover Vaccination period)
Drug page: NVX-CoV2373 adjuvated lipid nanoparticle
Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
Also known as: NVX-CoV2373
Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
Also known as: Sodium chloride 0.9% (BP, sterile)
Drug page: NVX-CoV2373 adjuvated lipid nanoparticle
In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
Also known as: NVX-CoV2373
In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
Also known as: Sodium chloride 0.9% (BP, sterile)
Drug page: NVX-CoV2373 adjuvated lipid nanoparticle
In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
Also known as: NVX-CoV2373
Drug page: NVX-CoV2373 adjuvated lipid nanoparticle
In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
Also known as: NVX-CoV2373
Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)
Number of participants with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Time frame: Day 28 to Day 750
Pediatric Expansion: Reactogenicity Incidence and Severity
Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).
Time frame: Day 0 to Day 27
Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49
Number of participants with mild, moderate, or severe MAAEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).
Time frame: Day 0 to Day 49
Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49
Number of participants with mild, moderate, or severe AEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).
Time frame: Day 0 to Day 49
Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points
Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through specified time points approximately every 3 and 6 months.
Time frame: Day 90 to Day 750
Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Specified Time Points
Number of participants with mild, moderate, or severe SAEs attributed to study vaccine through specified time points approximately every 3 and 6 months.
Time frame: Day 90 to Day 750
Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Specified Time Points
Number of participants with mild, moderate, or severe AESIs attributed to study vaccine through specified time points approximately every 3 and 6 months.
Time frame: Day 90 to Day 750
Pediatric Expansion: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe SAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 90 to Day 750
Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 90 to Day 750
Pediatric Expansion: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe AESIs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 90 to Day 750
Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points
Number of participants with antibodies to SARS-CoV-2 NP at Day 35 to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.
Time frame: Day 35
Pediatric Expansion: Deaths Due to Any Cause
Number of participants who died during the study due to any cause.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Participants with Symptomatic Moderate or Severe COVID-19
Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic moderate or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Time frame: Day 28 to Day 750
Adult Main Study and Pediatric Expansion: Participants with Any Symptomatic COVID-19
Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with any symptomatic COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Time frame: Day 28 to Day 750
Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs)
Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs)
Neutralizing antibody activity as detected by MN as expressed as GMFRs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs
Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Serum IgG Antibody Levels Expressed as GMFRs
Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs
Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs
Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Days 0, 35 and at specified time points through EoS.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points
Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points
Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points
Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points
Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as GMTs at Later Time Points
Neutralizing antibody activity as detected by MN as expressed as GMTs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points
Neutralizing antibody activity as detected by MN as expressed as GMFRs at Months 6, 12, 18, and 24.
Time frame: Day 165 to Day 750
Adult Main Study and Pediatric Expansion: Description of Course, Treatment and Severity of COVID-19
Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case via the Endpoint Form.
Time frame: Day 28 to Day 750
Adult Main Study: Reactogenicity Incidence and Severity
Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).
Time frame: Day 0 to Day 27
Adult Main Study: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49
Number of participants with mild, moderate, or severe MAAEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).
Time frame: Day 0 to Day 49
Adult Main Study: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49
Number of participants with mild, moderate, or severe AEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).
Time frame: Day 0 to Day 49
Adult Main Study: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points
Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through specified time points approximately every 3 months.
Time frame: Day 90 to Day 750
Adult Main Study: Incidence and Severity of Serious Adverse Events (SAEs) Attributed to Study Vaccine Through Specified Time Points
Number of participants with mild, moderate, or severe SAEs attributed to study vaccine through specified time points approximately every 3 months.
Time frame: Day 90 to Day 750
Adult Main Study: Incidence and Severity of Adverse Events of Special Interest (AESIs) Attributed to Study Vaccine Through Specified Time Points
Number of participants with mild, moderate, or severe AESIs attributed to study vaccine through specified time points approximately every 3 months.
Time frame: Day 90 to Day 750
Adult Main Study: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe SAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 90 to Day 750
Adult Main Study: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 360 to Day 750
Adult Main Study: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24
Number of participants with mild, moderate, or severe AESIs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.
Time frame: Day 360 to Day 750
Adult Main Study and Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points
Number of participants with antibodies to SARS-CoV-2 NP at Days 0 and 35, or at specified time points through EoS to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point
Number of participants with antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic.
Time frame: Day 0 to Day 750
Adult Main Study: IgG antibodies to SARS-CoV-2 rS at Day 35 After First Crossover Vaccination
The ratio of geometric mean IgG antibody concentrations will be computed at Day 35 for the new manufacturing process versus the old manufacturing process using the data collected from 300 active vaccine recipients 18 to ≤ 64 years of age enrolled at selected study sites.
Time frame: Day 35 after the first crossover vaccination
Adult Main Study : Deaths Due to Any Cause
Number of participants who died during the study due to any cause.
Time frame: Day 0 to Day 750
Adult Main Study and Pediatric Expansion: Participants with 1st episode of positive Polymerase Chain Reaction (PCR) for Coronavirus Disease 2019 (COVID-19) due to a variant not considered as a "variant of concern/interest"
Number of participants with first episode of PCR-positive COVID-19, as defined under the primary endpoint, shown by gene sequencing to represent a variant not considered as a "variant of concern/interest" according to the CDC Variants Classification.
Time frame: Day 28 to Day 750
Booster Amendment: Participants with symptomatic mild, moderate or severe COVID-19
First episode of PCR-positive mild, moderate, or severe COVID-19 occurring ≥ 7 days after the third (booster) vaccine dose.
Time frame: Day 0 to Day 7
Booster Amendment: Participants with PCR positive moderate-to-severe COVID-19
First episode of PCR-positive moderate-to-severe COVID-19 occurring ≥ 7 days after the third (booster) vaccine dose.
Time frame: Day 0 to Day 7
Booster Amendment: Participants with PCR positive COVID-19 due to a variant not considered "variant of interest/concern"
First episode of PCR-positive COVID-19 occurring ≥7 days after the third (booster) vaccine dose and shown by gene sequencing to represent a variant not considered as a "variant of concern/interest" according to the CDC Variants Classification
Time frame: Day 0 to Day 7
Booster Amendment: Participants with PCR positive COVID-19 due to a 'variant of concern/interest"
First episode of PCR-positive COVID-19 occurring ≥7 days after the third (booster) vaccine dose, and shown by gene sequencing to represent a "variant of concern/interest" according to the CDC Variants Classification.
Time frame: Day 0 to Day 7
Booster Amendment: Neutralizing antibody activity expressed as GMT
Neutralizing antibody titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.
Time frame: Day 0 to Day 28
Booster Amendment: Neutralizing antibody activity expressed as GMFR
Neutralizing antibody titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.
Time frame: Day 0 to Day 28
Booster Amendment: Serum IgG antibody levels expressed as GMT
Serum levels of IgG to SARS-CoV-2 S protein from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.
Time frame: Day 0 to Day 28
Booster Amendment: Serum IgG antibody levels expressed as GMFR
Serum levels of IgG to SARS-CoV-2 S protein from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.
Time frame: Day 0 to Day 28
Booster Amendment: hACE2 receptor binding inhibition assay expressed as GMT
hACE2 inhibition titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.
Time frame: Day 0 to Day 28
Booster Amendment: hACE2 receptor binding inhibition assay expressed as GMFR
hACE2 inhibition titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.
Time frame: Day 0 to Day 28
Booster Amendment: Incidence and severity of unsolicited AE's
Incidence and severity of unsolicited AEs through 28 days after the third (booster) vaccine dose.
Time frame: Day 0 to Day 28
Booster Amendment: Incidence and severity of MAAE's, SAE's and AESI's
Incidence and severity of MAAEs attributed to study vaccine, SAEs and AESIs through EoS.
Time frame: Day 0 to Day 720
Booster Amendment: Description of course, treatment and severity of COVID-19
Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case occurring ≥7 days after the third (booster) vaccine dose via the Endpoint Form.
Time frame: Day 0 to Day 7
Booster Amendment: Reactogenicity Incidence and Severity
Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of the third (booster) vaccination and subsequent 6 days.
Time frame: Day0 to Day 7
Booster Amendment: Deaths Due to Any Cause
Number of participants who died during the study due to any cause.
Time frame: Day 0 to Day 720
Site Specific Sub Study: Serum IgG to the SARS-CoV-2 spike protein expressed as GMEU
IgG geometric mean ELISA unit concentrations (EU/ml) to the SARS-CoV-2 spike protein at Day 28 following the second booster dose.
Time frame: Day 28
Site Specific Sub Study: Serum IgG antibody expressed as GMFR
IgG Geometric Mean Fold Rises (GMFR) at Day 28 post second booster dose relative to Day 28 post-first booster dose.
Time frame: Day 28
Site Specific Sub Study: Serum IgG to the SARS-CoV-2 spike protein expressed as SPR
Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in IgG ELISA unit concentrations to the SARS-CoV-2 spike protein at Day 28 post second booster dose.
Time frame: Day 28
Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as GMTs
hACE2 inhibition assay titers (GMTs) at Day 28 post second booster dose.
Time frame: Day 28
Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as GMFR
hACE2 GMFR at Day 28 post second booster dose relative to Day 28 post-first booster dose.
Time frame: Day 28
Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as SPR
Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in hACE2 inhibition assay titers at Day 28 post-second booster dose.Incidence, severity, and duration of solicited adverse events for the 7 days period following the second booster dose.
Time frame: Day 28
Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as GMTs
MN50 geometric mean titers to the SARS-CoV-2 wild-type virus at Day 28 post second booster dose.
Time frame: Day 28
Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as GMFR
MN50 GMFR at Day 28 post second booster dose relative to Day 28 post-first booster dose.
Time frame: Day 28
Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as SPR
Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in MN50 titers concentrations to the wild-type virus at Day 28 post second booster dose.
Time frame: Day 28
Showing the first 100 of 154 sites across 3 countries. Choose a country and city above to see the rest.
Plan to share: No
Ran from Dec 2020 to primary completion in Apr 2023, 27 months.
Of 42 phase 3 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle
Severe Acute Respiratory Syndrome →